AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33347829
Drug: Camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab plus chemotherapy (carboplatin and pemetrexed)
Trial: 36340667
Drug: Intrauterine injection
RxNorm normalized name: ETHIODIZED OIL 480 mg in 1 mL INTRAUTERINE INJECTION [LIPIODOL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine injection of autologous PRP
Trial: 36340667
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of fetal transfer without intrauterine PRP injection
Trial: 35410938
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OXY) spray (24 IU)
Trial: 35410938
Drug: Placebo (PLC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLC) spray plus oral naltrexone (NTX) (50 mg)
Trial: 35329972
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with a new nutritional product developed by the Grand Fontaine Laboratories
Trial: 33728044
Drug: Medicines and
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medicines and Alcohol Consultation (MAC) intervention
Trial: 33026570
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy alone (Control)
Trial: 35064716
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg for 7 days
Trial: 35064716
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg single dose
Trial: 35448154
Drug: Intensive arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive arm (8 phone counseling sessions + 8 weeks of nicotine replacement therapy)
Trial: 35448154
Drug: Minimal arm
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal arm (3 sessions + 2 weeks of nicotine replacement therapy)
Trial: 34052928
Drug: Infrared laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared laser treatment (0.6 J per point, 214.28 J/cm2 energy density, 17.85 W/cm2 intensity)
Trial: 34052928
Drug: Red laser
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red laser treatment (0.6 J per point, 214.28 J/cm2 energy density, 17.85 W/cm2 intensity)
Trial: 35821731
Drug: Rapid Treatment
RxNorm normalized name: trapidil
DrugBank: Trapidil (DB09283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Treatment
Trial: 35212136
Drug: Intralesional Purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional Purified Protein Derivative (PPD) 10 IU (0.1 ml)
Trial: 32356170
Drug: Subacromial corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial corticosteroid injection (SCI)
Trial: 32356170
Drug: Subacromial corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial corticosteroid injection plus suprascapular nerve block (SSNB)
Trial: 33270009
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement treatment in England
Trial: 33170261
Drug: Sodium Benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Benzoate (500 mg twice daily)
Trial: 34468080
Drug: Filgotinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib (200 mg once daily for 11 days)
Trial: 34501669
Drug: Standard paper–pencil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard paper–pencil treatment
Trial: 35293973
Drug: Early supplemental
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early supplemental parenteral nutrition (E‐SPN) starting on day 3 after surgery
Trial: 35293973
Drug: Late supplemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late supplemental parenteral nutrition (L‐SPN) starting on day 8 after surgery
Trial: 32113839
Drug: GCs +
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCs + LEF (20 mg/day)
Trial: 32113839
Drug: GCs monotherapy
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCs monotherapy
Trial: 36232122
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy with intramuscular injections of pIRES/VEGF165/HGF plasmids and 1 month of ANG-1 plasmids
Trial: 35244019
Drug: Hysteroscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysteroscopic treatment of Asherman syndrome
Trial: 35078490
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy (SoC-CT) without SBRT
Trial: 33327737
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg twice/day
Trial: 33952741
Drug: Grains of
RxNorm normalized name: barley grain
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grains of Paradise (GP) extract (40 mg/d)
Trial: 32541510
Drug: Yuanhu Zhitong
RxNorm normalized name: METHYL SALICYLATE 13 g / MENTHOL 9 g / CAMPHOR (SYNTHETIC) 11 g TOPICAL PATCH [KGS Zhitong Gao Medicated Plaster Extra Strength]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yuanhu Zhitong dropping pills
Trial: 32541510
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium sustained-release capsule
Trial: 616081112
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac 5mg/ml
Trial: 616081112
Drug: Topical bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bromfenac 9mg/ml
Trial: 32451827
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (15 mg/kg/dose)
Trial: 32451827
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (10 mg/kg/dose)
Trial: 35758374
Drug: High-dose Resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Resveratrol (500 mg/d)
Trial: 35758374
Drug: Middle-dose Resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle-dose Resveratrol (250 mg/d)
Trial: 35758374
Drug: Low-dose Resveratrol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Resveratrol (125 mg/d)
Trial: 34264701
Drug: TranS‐C +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TranS‐C + UC (n = 61; 8 individual weekly sessions)
Trial: 34974435
Drug: Neurofeedback treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofeedback treatment reinforcing reductions in theta activity
Trial: 35737076
Drug: Active Control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Control Treatment (AC)
Trial: 32250021
Drug: Daprodustat 2-mg
RxNorm normalized name: daprodustat 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daprodustat 2-mg tablet
Trial: 32250021
Drug: Daprodustat 4-mg
RxNorm normalized name: daprodustat 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daprodustat 4-mg tablet
Trial: 36342737
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide system during MFU-V treatment
Trial: 33135429
Drug: Lacidipine (4–6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (4–6 mg/day)
Trial: 33135429
Drug: Amlodipine (5–7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5–7.5 mg/day)
Trial: 35121270
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for antenatal depression
Trial: 33161581
Drug: Traditional training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional training videos on CBCT and implant planning
Trial: 34635140
Drug: Wearable +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable + Symptom Data Algo (Ava bracelet data + Daily Symptom Diary data)
Trial: 34635140
Drug: Symptom Only
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom Only Algo (Daily Symptom Diary data alone)
Trial: 70655980
Drug: Everolimus (EVR)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVR) 3-8 ng/mL
Trial: 70655980
Drug: Everolimus (EVR)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVR) 6-12 ng/mL
Trial: 70655980
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Mycophenolate sodium 1.44 g/day with standard dose CsA)
Trial: 33275070
Drug: Antibiotic use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic use in last 4 weeks
Trial: 32631427
Drug: Eurythmy therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurythmy therapy (ERYT)
Trial: 32622346
Drug: Intensive BP
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive BP therapy (<120/80 mm Hg)
Trial: 32622346
Drug: Standard BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BP therapy (<140/90 mm Hg)
Trial: 32023922
Drug: Angelica Gigas
RxNorm normalized name: ANGELICA GIGAS ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angelica Gigas Nakai Extract (AGNE) 1 g/day (200 mg/dose) for 12 weeks
Trial: 34688549
Drug: Photon radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Photon radiation therapy (IMRT)
Trial: 33302644
Drug: Fan-zhen Jie-ci
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fan-zhen Jie-ci (FZJC) acupuncture therapy
Trial: 32144927
Drug: Routine acupuncture
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine acupuncture treatment
Trial: 32107266
Drug: SPIOMET treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPIOMET treatment (low-dose combination of spironolactone, pioglitazone, and metformin)
Trial: 32107266
Drug: Oral contraception-based
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraception-based treatment
Trial: 33091857
Drug: Propolis oral
RxNorm normalized name: propolis Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis oral spray (2-4 sprays three times/day for five days, total polyphenol content 15 mg/ml)
Trial: 33091857
Drug: Propolis oral
RxNorm normalized name: propolis Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis oral spray
Trial: 34750839
Drug: Rocuronium 12.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 12.0 μg·kg‐1 ·min‐1
Trial: 34750839
Drug: Rocuronium 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 6.0 μg·kg‐1 ·min‐1
Trial: 34750839
Drug: Rocuronium 9.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 9.0 μg·kg‐1 ·min‐1
Trial: 34750839
Drug: Rocuronium 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 6.0 μg·kg‐1 ·min‐1 and 9.0 μg·kg‐1 ·min‐1
Trial: 35177299
Drug: Pfizer vaccine
RxNorm normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer vaccine
Trial: 37379532
Drug: AstraZeneca vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AstraZeneca vaccine
Trial: 36249252
Drug: Sinopharm vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinopharm vaccine
Trial: 32648393
Drug: Waiting for
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting for treatment group
Trial: 35451469
Drug: 3.2 g
RxNorm normalized name: OATMEAL 2.3 g in 113.2 g TOPICAL CREAM [EczeNil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 g of magnesium daily (4 tablets of 0.4 g each twice daily) for 72 hours preoperatively and 1.6 g of magnesium on the day of surgery
Trial: 32636239
Drug: TMBRB predicting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMBRB predicting immunotherapy efficacy.
Trial: 33481482
Drug: Simulated sunlight
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated sunlight (1.3× standard erythemal dose, three times per week for 4 weeks and then once per week for 8 weeks)
Trial: 33481482
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 (1000 IU·d‐1 for 4 weeks and then 400 IU·d‐1 for 8 weeks)
Trial: 33370477
Drug: third-party bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: third-party bone marrow-derived MSC infusion
Trial: 32534731
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid strategy (10 mL.kg‐1.h‐1 following institutional standard care protocol)
Trial: 33905827
Drug: Lavandula angustifolia
RxNorm normalized name: Lavandula Angustifolia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavandula angustifolia essential oil inhalation for 29 days
Trial: 33905827
Drug: Placebo (sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sunflower oil) inhalation for 29 days
Trial: 36397215
Drug: Sham electroacupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham electroacupuncture at non-acupoints with shallow needling, no current, same treatment duration as EA group.
Trial: 35592490
Drug: Duloxetine (10-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (10-week treatment)
Trial: 35592490
Drug: Desvenlafaxine (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (12-week treatment)
Trial: 32846775
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy Exercises (PTE)
Trial: 32846775
Drug: Wharton Jelly
RxNorm normalized name: Human Umbilical Cord Wharton's Jelly-derived Mesenchymal Stem Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wharton Jelly mesenchymal stem cell (WJ‐MSCs) injections
Trial: 32203712
Drug: Palivizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab (15 mg/kg, intramuscular injections during RSV season)
Trial: 36370176
Drug: Collagen peptides
RxNorm normalized name: CASTOR OIL 100 g in 100 mL TOPICAL OIL [Anyi Beauty Biotin With Collagen Peptides Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen peptides (CP) 10 g·day‐1
Trial: 33470341
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg codeine and 500 mg acetaminophen (4 times a day for 4 days)
Trial: 32717180
Drug: Second-look surgery
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-look surgery plus oxaliplatin-HIPEC (oxaliplatin 460 mg/m2, or oxaliplatin 300 mg/m2 plus irinotecan 200 mg/m2, plus intravenous fluorouracil 400 mg/m2)
Trial: 34584543
Drug: MIXTIVA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MIXTIVA infusion (remifentanil/propofol at a proportion of 2/1,000 or 3/1,000)
Trial: 34584543
Drug: Standard TIVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TIVA with separate remifentanil and propofol infusions (Control Group I)
Trial: 34584543
Drug: MIXTIVA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MIXTIVA infusion (Group III with remifentanil concentration 30 µg/ml)
Trial: 34584543
Drug: MIXTIVA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MIXTIVA infusion (Group II with remifentanil concentration 20 µg/ml)
Trial: 34084153
Drug: CDCA 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA 1.25 g
Trial: 34084153
Drug: CDCA 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA 1.25 g + colesevelam 3.75 g
Trial: 34084153
Drug: CDCA 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA 1.25 g (with mixed meal)
Trial: 34084153
Drug: colesevelam 3.75
RxNorm normalized name: colesevelam 3.75 g oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colesevelam 3.75 g (with mixed meal)
Trial: 34084153
Drug: colesevelam 3.75
RxNorm normalized name: colesevelam 3.75 g oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colesevelam 3.75 g × 2 (with mixed meal)
Trial: 32308366
Drug: N-butylphthalide (NBP)
RxNorm normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-butylphthalide (NBP) and dexamethasone (DXM) combined with hyperbaric oxygen (HBO) therapy
Trial: 32308366
Drug: HBO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBO therapy as monotherapy (Control)
Trial: 32197629
Drug: NEMEX-TJR twice
RxNorm normalized name: Nemex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEMEX-TJR twice weekly for 12 weeks combined with two sessions of PNE
Trial: 33549019
Drug: Yinxieling tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinxieling tablets
Trial: 33570017
Drug: D-cycloserine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (250 mg)
Trial: 33389761
Drug: Nano-curcumin (Sinacurcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-curcumin (Sinacurcumin soft gel, 40 mg curcuminoids as nanomicelles, two capsules twice a day)
Trial: 35938937
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Dolichos biflorus seeds (1,600 mg)
Trial: 35938937
Drug: Extract of
RxNorm normalized name: Extract of tomato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Cynodon dactylon rhizome (1,600 mg)
Trial: 34362522
Drug: Astaxanthin (ASTA)
DrugBank: Astaxanthin (DB06543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin (ASTA) at concentrations of 5, 10, and 20 μmol/L
Trial: 36498603
Drug: 3D adjustable
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D adjustable posture corrective orthotic (PCO) added to a multimodal program; performed mirror image therapy for 20–30 min while walking on a treadmill 2–3 times per week for 10 weeks.
Trial: 32950989
Drug: Nasal device
RxNorm normalized name: Benzedrex, 250 mg nasal device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal device (soft silicone insert) for 5-12 hours daily
Trial: 36653409
Drug: Caffeine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (150 mg × 3 times/day)
Trial: 34360105
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g serving
Trial: 32843084
Drug: Fire needle
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fire needle therapy
Trial: 33834343
Drug: Tomato cultivars
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato cultivars with 3.6 mg kg‐1 Cd
Trial: 33834343
Drug: Tomato cultivars
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato cultivars with 12 mg kg‐1 Cd
Trial: 33834343
Drug: Tomato cultivars
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato cultivars with long-term exposure to 12 mg kg‐1 Cd
Trial: 35000893
Drug: Experimental formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formula (EF) with higher protein level of 3.4 g/100 kcal and improved fat blend
Trial: 35000893
Drug: Control formula
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formula (CF) with protein level of 2.9 g/100 kcal and standard fat blend
Trial: 33116455
Drug: Icenticaftor 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icenticaftor 300 mg b.i.d.
Trial: 32005992
Drug: Immediate iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate iron treatment (ferrous sulfate 2 mg · kg‐1 · d‐1 for 3 months)
Trial: 32005992
Drug: Delayed iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed iron treatment (ferrous sulfate 2 mg · kg‐1 · d‐1 for 3 months, starting 28 days after antimalarial treatment)
Trial: 32705319
Drug: Peri-articular infiltration
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-articular infiltration of morphine, ropivacaine, and epinephrine